Quoin says FDA grants rare pediatric disease designation for QRX003 in peeling skin syndrome

• FDA granted Rare Pediatric Disease designation for QRX003 in Peeling Skin Syndrome, extending a prior designation in Netherton Syndrome.
• An approved NDA for Peeling Skin Syndrome could qualify QRX003 for a Priority Review Voucher that can be sold or transferred.
• Management estimated two potential vouchers could exceed $300 million in aggregate non-dilutive value, based on recent trading levels.
• Quoin expects to start a Phase 2 study in 2H 2026, enrolling up to 12 pediatric and adult patients in the U.S. and Europe.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080830PRIMZONEFULLFEED9822136) on September 08, 2026, and is solely responsible for the information contained therein.